XNYSMYO
Market cap136mUSD
Jan 10, Last price
6.51USD
1D
-5.92%
1Q
68.22%
IPO
-97.06%
Name
Myomo Inc
Chart & Performance
P/E
—
P/S
7.08
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
135.17%
Rev. gr., 5y
51.09%
Revenues
19m
+23.70%
Net income
-8m
L-24.00%
CFO
-6m
L-39.68%
Earnings
Mar 05, 2025
Profile
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 19,241 23.70% | 15,555 12.26% | |||||||
Cost of revenue | 27,931 | 26,227 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (8,690) | (10,672) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 156 | 70 | |||||||
Tax Rate | |||||||||
NOPAT | (8,846) | (10,742) | |||||||
Net income | (8,148) -24.00% | (10,721) 3.36% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 9,722 | 377 | |||||||
BB yield | -6.58% | -10.45% | |||||||
| Debt | |||||||||
Debt current | 972 | 354 | |||||||
Long-term debt | 716 | 754 | |||||||
Deferred revenue | 498 | ||||||||
Other long-term liabilities | 498 | ||||||||
Net debt | (7,177) | (4,371) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (6,173) | (10,234) | |||||||
CAPEX | (146) | (112) | |||||||
Cash from investing activities | (2,030) | (311) | |||||||
Cash from financing activities | 9,713 | 377 | |||||||
FCF | (8,737) | (11,158) | |||||||
| Balance | |||||||||
Cash | 8,866 | 5,346 | |||||||
Long term investments | 132 | ||||||||
Excess cash | 7,904 | 4,701 | |||||||
Stockholders' equity | (96,844) | (88,739) | |||||||
Invested Capital | 106,921 | 95,605 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 29,499 | 7,051 | |||||||
Price | 5.01 879.66% | 0.51 -92.53% | |||||||
Market cap | 147,792 3,998.37% | 3,606 -90.96% | |||||||
EV | 140,614 | (765) | |||||||
EBITDA | (8,172) | (10,130) | |||||||
EV/EBITDA | 0.08 | ||||||||
Interest | 89 | ||||||||
Interest/NOPBT | |||||||||